# US 2012/0059026 A1 · Antimicrobial agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0059026 A1
- Document ID: US20120059026A1
- Status: Published application
- Kind: A1
- Application number: 13/266,740
- Filed: 2010-04-30
- Published: 2012-03-08
- Earliest claimed: 2009-04-30
- Assignees: University of Medicine and Dentistry of New Jersey; Rutgers, The State University of New Jersey
- Inventors: Edmond J. LaVoie; Daniel S. Pilch; Ajit Parhi; Malvika Kaul
- Web page: https://patentgrep.com/patent/US20120059026A1

## CPC

- C07D 455/03: containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- A61P 31/04: Antibacterial agents
- C07D 217/02: with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D 217/10: Quaternary compounds
- C07D 217/12: with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a compound of formula (I): or a salt or prodrug thereof, wherein Y, W, Z, Z1, Z2, Z3, Z4, and R1-R12 have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as antibacterial agents.

## Claims

### Claim 1

A compound of formula I:
wherein:
the dashed line between Y and W represents a single or double bond;
when Y is —CR2—, Z is —(CR132)2— or —CR14═CR14— and R12 is a bond; W is N or (NRa)+X−;
when Y is —CR2— and Z is absent; W is NRb or (NRcRd)+X−;
when Y is —C═, Z is —(CR132)2— or —CR14═CR14— and R12 is a bond; W is N+X−; or
when Y is —C═and Z is absent; W is N or (NRa)+X−;
X− is a pharmaceutically suitable counterion;
Z1, Z2, Z3 and Z4 are each independently O, S or NRe; or R8—Z1—, R9—Z2—, R10—Z3—, and R11—Z4— can each independently be H, optionally substituted aryl or optionally substituted heteroaryl;
R1 is H, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, aryloxy or arylthio; and R2 is H or (C1-C6)alkyl, wherein any (C1-C6)alkyl, (C1-C6)alkoxy, and (C1-C6)alkylthio of R1 and R2 is optionally substituted with one or more groups selected from halo, cyano, oxo (═O), (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi, and wherein any aryloxy, or arylthio of R1 and R2 is optionally substituted with one or more groups selected from halo, cyano, (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi; or R1 and R2 together with the carbon to which they are attached form a carbonyl group;
at least one of R3, R4, R5, R6 and R7 is hydroxyl, carboxy, cyano, alkoxy, CF3SO3—, alkyl, substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted aryl, optionally substituted arylalkanoyl, Rk, or optionally substituted heteroaryl, wherein substituted alkyl is an alkyl group with 1 to 5 substituent groups independently selected from cycloalkyl, substituted cycloalkyl, alkoxycarbonyl, cyano, halo, hydroxyl, oxo, carboxy, aryloxy, heteroaryloxy, heterocyclooxy, nitro, sulfo, —S(O)2NRnRp, —N(Rn)S(O)2Rp, and —NRnRp, wherein Rn and Rp may be the same or different and are chosen from hydrogen, alkyl, arylalkyl, heteroarylalkyl, cycloalkyl, substituted cycloalkyl, aryl, heteroaryl and heterocyclic; and the remainder of R3, R4, R5, R6 and R7 are independently H, halo, nitro, sulfo, —S(O)2NRnRp, —N(Rn)S(O)2Rp, —NRhRi optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted aryl, or optionally substituted heteroaryl; or R3 is —Z13—R13 wherein Z13 is O, S or NRe and R13 is (C1-C6)alkyl, substituted (C1-C6)alkyl, (C1-C6)alkanoyl or —C(═O)NRfRg or R13 and R9 together with the atoms to which they are attached form a 5 to 7 membered ring; or R6 and R7 together with the atoms to which they are attached form a 5 to 6 membered heterocycle wherein the heterocycle is optionally fused with an optionally substituted aryl.
when Z is absent R12 is H, alkyl, halo, —NRhRi, NO2, aryl, heteroaryl, aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl, aryl(C1-C6)alkanoyl or heteroaryl(C1-C6)alkanoyl wherein alkyl, aryl, heteroaryl, aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl, aryl(C1-C6)alkanoyl or heteroaryl(C1-C6)alkanoyl are optionally substituted with one or more groups selected from halo, cyano, (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi;
R8 and R9 are each independently, (C1-C6)alkyl, (C1-C6)alkanoyl or —C(═O)NRfRg or R8 and R9 together with the atoms to which they are attached form a 5 to 7 membered ring; or R8—Z1— and R9—Z2— can each independently be H;
R10 and R11 are each independently, (C1-C6)alkyl, (C1-C6)alkanoyl or —C(═O)NRfRg or R10 and R11 together with the atoms to which they are attached form a 5 to 7 membered ring; or R10—Z3—, and R11—Z4— can each independently be H;
each R13 is independently H, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, aryloxy or arylthio wherein any (C1-C6)alkyl, (C1-C6)alkoxy, and (C1-C6)alkylthio of R13 is optionally substituted with one or more groups selected from halo, cyano, oxo (═O), (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi, and wherein any aryloxy, or arylthio of R13 is optionally substituted with one or more groups selected from halo, cyano, (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi;
each R14 is independently H, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, aryloxy or arylthio wherein any (C1-C6)alkyl, (C1-C6)alkoxy, and (C1-C6)alkylthio of R14 is optionally substituted with one or more groups selected from halo, cyano, oxo (═O), (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi, and wherein any aryloxy, or arylthio of R14 is optionally substituted with one or more groups selected from halo, cyano, (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi;
Ra is (C1-C6)alkyl wherein (C1-C6)alkyl is optionally substituted with one or more groups independently selected from halo, cyano, oxo (═O), (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi;
Rb is H or (C1-C6)alkyl wherein (C1-C6)alkyl is optionally substituted with one or more groups independently selected from halo, cyano, oxo (═O), (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi;
Rc and Rd are each independently selected from (C1-C6)alkyl wherein (C1-C6)alkyl is optionally substituted with one or more groups independently selected from halo, cyano, oxo (═O), (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi;
each Re is independently H or (C1-C6)alkyl wherein (C1-C6)alkyl is optionally substituted with one or more halo;
Rf and Rg are each independently H, (C1-C6)alkyl, aryl, heteroaryl, aryl(C1-C6) alkyl or heteroaryl(C1-C6) alkyl; or Rf and Rg together with the nitrogen to which they are attached form a morpholino, piperazino, pyrrolidino or piperidino;
Rh and Ri are each independently H, (C1-C6)alkyl, aryl, heteroaryl, aryl(C1-C6) alkyl or heteroaryl(C1-C6) alkyl; or Rh and Ritogether with the nitrogen to which they are attached form a morpholino, piperazino, pyrrolidino or piperidino;
each Rk is independently selected from an aryl optionally substituted with one or more Rm, an alkyl substituted with one or more heterocycle, and an alkyl substituted with one or more substituted heterocycle;
each Rm is independently, alkoxy, substituted alkoxy, heteroaryl, heterocycle, or —S(O)2NRuRv; and
each Ru and Rv is independently H, (C1-C6)alkyl, aryl, heteroaryl, aryl(C1-C6)alkyl, or heteroaryl(C1-C6)alkyl; or Rm and Rn together with the nitrogen to which they are attached form a morpholino, piperazino, pyrrolidino or piperidino;
or a salt or prodrug thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein:
the dashed line between Y and W represents a single or double bond;
when Y is —CR2—, Z is —(CR132)2— or CR14═CR14— and R12 is a bond; W is N or (NRa)+X−;
when Y is —CR2— and Z is absent; W is NRb or (NRcRd)+X−;
when Y is —C═, Z is —(CR132)2— or —CR14═CR14— and R12 is a bond; W is N+X−; or
when Y is —C═and Z is absent; W is N or (NRa)+X−;
X− is a pharmaceutically suitable counterion;
Z1, Z2, Z3 and Z4 are each independently O, S or NRe;
R1 is H, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, aryloxy or arylthio; and R2 is H or (C1-C6)alkyl, wherein any (C1-C6)alkyl, (C1-C6)alkoxy, and (C1-C6)alkylthio of R1 and R2 is optionally substituted with one or more groups selected from halo, cyano, oxo (═O), (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi, and wherein any aryloxy, or arylthio of R1 and R2 is optionally substituted with one or more groups selected from halo, cyano, (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi; or R1 and R2 together with the carbon to which they are attached form a carbonyl group;
at least one of R3, R4, R5, R6 and R7 is aryl, heteroaryl, aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl, aryl(C1-C6)alkanoyl or heteroaryl(C1-C6)alkanoyl and the remainder are each independently H, alkyl, halo, —NRhRi, NO2, aryl, heteroaryl, aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl, aryl(C1-C6)alkanoyl or heteroaryl(C1-C6)alkanoyl wherein the alkyl, aryl, heteroaryl, aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl, aryl(C1-C6)alkanoyl or heteroaryl(C1-C6)alkanoyl of R3, R4, R5, R6 and R7 is optionally substituted with one or more groups selected from halo, cyano, (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi;
when Z is absent R12 is H, alkyl, halo, —NRhRi, NO2, aryl, heteroaryl, aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl, aryl(C1-C6)alkanoyl or heteroaryl(C1-C6)alkanoyl wherein alkyl, aryl, heteroaryl, aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl, aryl(C1-C6)alkanoyl or heteroaryl(C1-C6)alkanoyl are optionally substituted with one or more groups selected from halo, cyano, (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi;
R8 and R9 are each independently, (C1-C6)alkyl, (C1-C6)alkanoyl or —C(═O)NRfRg or R8 and R9 together with the atoms to which they are attached form a 5 to 7 membered ring;
R10 and R11 are each independently, (C1-C6)alkyl, (C1-C6)alkanoyl or —C(═O)NRfRg or R10 and R11 together with the atoms to which they are attached form a 5 to 7 membered ring;
each R13 is independently H, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, aryloxy or arylthio wherein any (C1-C6)alkyl, (C1-C6)alkoxy, and (C1-C6)alkylthio of R13 is optionally substituted with one or more groups selected from halo, cyano, oxo (═O), (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi, and wherein any aryloxy, or arylthio of R13 is optionally substituted with one or more groups selected from halo, cyano, (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi;
each R14 is independently H, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, aryloxy or arylthio wherein any (C1-C6)alkyl, (C1-C6)alkoxy, and (C1-C6)alkylthio of R14 is optionally substituted with one or more groups selected from halo, cyano, oxo (═O), (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and NRhRi, and wherein any aryloxy, or arylthio of R14 is optionally substituted with one or more groups selected from halo, cyano, (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi;
Ra is (C1-C6)alkyl wherein (C1-C6)alkyl is optionally substituted with one or more groups independently selected from halo, cyano, oxo (═O), (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi;
Rb is H or (C1-C6)alkyl wherein (C1-C6)alkyl is optionally substituted with one or more groups independently selected from halo, cyano, oxo (═O), (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi;
Rc and Rd are each independently selected from (C1-C6)alkyl wherein (C1-C6)alkyl is optionally substituted with one or more groups independently selected from halo, cyano, oxo (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NO2, hydroxy, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and —NRhRi;
each Re is independently H or (C1-C6)alkyl wherein (C1-C6)alkyl is optionally substituted with one or more halo;
Rf and Rg are each independently H, (C1-C6)alkyl, aryl, heteroaryl, aryl(C1-C6) alkyl or heteroaryl(C1-C6) alkyl; or Rf and Rg together with the nitrogen to which they are attached form a morpholino, piperazino, pyrrolidino or piperidino; and
Rh and Ri are each independently H, (C1-C6)alkyl, aryl, heteroaryl, aryl(C1-C6) alkyl or heteroaryl(C1-C6) alkyl; or Rf and Rg together with the nitrogen to which they are attached form a morpholino, piperazino, pyrrolidino or piperidino;
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 3 (depends on 1)

The compound of claim 1 which is a compound of the following formula:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 4 (depends on 1)

The compound of claim 1 which is a compound of the following formula:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 5 (depends on 1)

The compound of claim 1 which is a compound of the following formula:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 6 (depends on 1)

The compound of claim 1 which is a compound of the following formula:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 7 (depends on 1)

The compound of claim 1 which is a compound of the following formula:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 8 (depends on 1)

The compound of claim 1 which is a compound of the following formula:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 9 (depends on 1)

The compound of claim 1 which is a compound of the following formula:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 10 (depends on 1)

The compound of claim 1 which is a compound of formula Ih:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 11 (depends on 1)

The compound of claim 1 which is a compound of formula Ij:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 12 (depends on 1)

The compound of claim 1 which is a compound of formula Ik:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 13 (depends on 1)

The compound of claim 1 which is a compound of formula Im:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 14 (depends on 1)

The compound of claim 1 which is a compound of formula In:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 15 (depends on 1)

The compound of claim 1 which is a compound of formula Ip:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 16 (depends on 1)

The compound of claim 1 which is a compound of formula Ir:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim at position 17

17-38. (canceled)

### Claim 39 (depends on 1)

The compound of claim 1 which is selected from:
or a salt or prodrug thereof.

### Claim 40 (depends on 1)

The compound of claim 1 which is selected from:
or a prodrug thereof.

### Claim 41 (depends on 1)

The compound of claim 1 which is selected from:
or a salt or prodrug thereof.

### Claim 42 (depends on 1)

The compound of claim 1 which is selected from:
or a salt or prodrug thereof.

### Claim 43 (depends on 1)

The compound of claim 1 which is selected from:
or a salt or prodrug thereof.

### Claim 44 (depends on 1)

The compound of claim 1 which is selected from:
or a salt or prodrug thereof.

### Claim at position 24

45-46. (canceled)

### Claim 47 (depends on 1)

A composition comprising a compound of formula I as described in claim 1, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable vehicle.

### Claim 48 (depends on 1)

A method for inhibiting FtsZ polymerization in a bacterium comprising contacting the bacterium with an amount of a compound of formula I as described in claim 1, or a pharmaceutically acceptable salt or prodrug thereof, effective to inhibit FtsZ polymerization.

### Claim 49 (depends on 1)

A method for inhibiting FtsZ Z-ring formation in a bacterium comprising contacting the bacterium with an amount of a compound of formula I as described in claim 1, or a pharmaceutically acceptable salt or prodrug thereof, effective to inhibit FtsZ Z-ring formation.

### Claim 50 (depends on 1)

A method for inhibiting the recruitment of divisome proteins in a bacterium comprising contacting the bacterium with an amount of a compound of formula I as described in claim 1, or a pharmaceutically acceptable salt or prodrug thereof, effective to inhibit the recruitment of divisome proteins.

### Claim 51 (depends on 1)

A method for treating a bacterial infection in a mammal comprising administering to the mammal an effective amount of a compound of formula I as described in as described in claim 1, or a pharmaceutically acceptable salt or prodrug thereof.

### Claim at position 30

52-60. (canceled)
